News
RDIF collaborates with India for one-shot Sputnik Light, Sputnik M vaccines
IMT News Desk
2 years ago
RDIF collaborates with India for one-shot Sputnik Light, Sputnik M vaccines
IMT News Desk
2 years ago
Results of a separate joint clinical trial of a combination of Sputnik Light with the AstraZeneca vaccine have demonstrated that it induces strong immunity and has a high safety profile
Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) is actively cooperating with India’s regulatory authorities on the registration of Sputnik Light (the one-shot vaccine based on human adenovirus serotype 26, the first component of the Sputnik V) as a standalone vaccine and a universal booster and expects it to be authorised in the country soon. A major partner of RDIF, Dr Reddy’s Laboratories, has conducted additional clinical trials of Sputnik Light in India. Positive data from these trials have also been presented to India's regulator.
One-shot Sputnik Light is a highly effective vaccine: the latest findings by the Gamaleya Center based on data from 28,000 subjects in Moscow have demonstrated that Sputnik Light administered standalone has 70 per cent efficacy against infection from the Delta variant of coronavirus during the first three months after vaccination. The vaccine is 75 per cent effective among subjects under the age of 60. Efficacy of Sputnik Light as a booster against Delta variant for other vaccines will be close to the efficacy against the Delta variant of the Sputnik V vaccine: over 83 per cent against infection and over 94 per cent against hospitalisation.
Sputnik Light has proven to be safe and highly effective by real-world vaccination data. In particular, the vaccine has demonstrated efficacy of between 78.6-83.7% among the elderly as confirmed by the Ministry of Health of Buenos Aires, Argentina. Paraguay’s Ministry of Health also found Sputnik Light to be 93.5 per cent effective during the country’s ongoing vaccination campaign.
Results of a separate joint clinical trial of a combination of Sputnik Light with the AstraZeneca vaccine have demonstrated that it induces strong immunity and has a high safety profile.
RDIF has also provided India’s regulator with documents for registration of Sputnik M – the vaccine for adolescents aged 12-17. Russia's Health Ministry registered Sputnik M on November 24, 2021. It has become a new member of the Sputnik vaccines family and is offered to international markets joining Sputnik V and Sputnik Light.
Recommended
